PTGES3 correlates with poor patient prognosis and immune infiltrates in lung adenocarcinoma [79] and is an oncogenic driver within a 10-gene metabolic panel in NSCLC [80]. Here, PTGES3 is linked to non-small cell lung carcinoma.